KRAS and neoplasm: Notably, PHGDH expression was significantly correlated with prognosis across multiple clinical subgroups, including female patients, T1‐2 and T3‐4 stages, N1‐2, M0, stage I/II and III/IV, MSI‐low (MSI‐L)/microsatellite stable (MSS), MSI‐high (MSI‐H), as well as tumours harbouring TP53 or KRAS mutations (Figure S10A–J).